Celgene Corp., of Summit, N.J., reported results from a pre-specified secondary endpoint analysis of MDS-005, a randomized, placebo-controlled phase III study of Revlimid (lenalidomide) compared with placebo in patients with non-del-5q myelodysplastic syndromes.